Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development cooperation agreement with Yikang Biological (Suzhou) Co., Ltd to develop a recombinant respiratory syncytial virus (RSV) vaccine aimed at preventing RSV-induced respiratory diseases. Under the terms of the agreement, Yikang will contribute its self-designed RSV antigen, and Recbio will provide its self-developed neoadjuvant. Financial details of the partnership have not been disclosed.
RSV: A Significant Threat to Public Health
Respiratory syncytial virus (RSV) is an extremely common and infectious virus that poses a significant risk of serious respiratory diseases, particularly to children, the elderly, and individuals with compromised immune function. The elderly, due to aging and decreased immunity, are at a high risk of developing severe RSV disease. Currently, no RSV preventative vaccine has been approved for marketing in China, where 2.2 million elderly people aged 65 and above suffer from severe RSV infections, a figure that contrasts with the global count of 8.6 million.
Company Profiles and Expertise
Yikang Bio, founded in 2017, specializes in the research and development of reverse vaccines based on the three-dimensional structure of proteins. Recbio, established in 2012, boasts a highly differentiated product portfolio that covers a range of diseases, including cervical cancer, herpes zoster, and COVID-19. This collaboration combines the expertise of both companies to address the unmet need for an RSV vaccine, potentially benefiting a vulnerable population segment both in China and globally.-Fineline Info & Tech
